Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The restless legs syndrome (RLS) is a common sensory-motor disorder of sleep/wake motor regulation with prevalence rates between 3% and 10%. In its more severe forms, RLS is a burdening disorder with disturbed sleep and significantly impaired quality of life. Restless legs symptoms are dramatically relieved with levodopa and dopamine agonists, which are first-line treatment for this disorder. In addition, opioids have been shown to provide a marked symptomatic relief. This unique responsiveness of RLS to both dopaminergic agents and opioids places it at the crossroad of the two systems implicated in the placebo response. Indeed, in recent large-scale studies a substantial placebo response was observed. We performed a meta-analysis to provide an evidence-based estimate of the magnitude of the placebo response in RLS. Search strategies included the electronic databases PubMed and the Cochrane Clinical Trials Registry (from 1966 to March 2007), the reference lists of retrieved articles, hand-searching abstract books of sleep, neurology and movement disorder congresses and visiting clinical trial register web sites. All randomized, double-blind, placebo-controlled studies exploring a pharmacological treatment in subjects with RLS were considered. Outcome measures from five domains were extracted: RLS severity, subjective sleep parameters, sleep parameters derived from nocturnal polysomnography, periodic leg movements during sleep (PLMS) and daytime functioning. We identified 60 clinical trials and 36 of them were eligible for the meta-analysis. In 24 trials, the pooled placebo response rate was 40.09% (95% CI: 31.99-48.19). The placebo effect was large for the primary outcome measure in most studies, which is the International Restless Legs Severity Scale (-1.48, CI: -1.81 to -1.14), notably smaller for other RLS severity scales, moderate for daytime functioning, small to moderate for subjective and objective sleep parameters, very small for PLMS and absent for sleep efficiency. This meta-analysis yields several implications for the planning of both clinical RLS treatment studies and basic research programs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
Approximate is Better than “Exact” for Interval Estimation of Binomial Proportions
Agresti, A., & Coull, B. A. (1998) · The American Statistician · doi:10.1080/00031305.1998.10480550 · Cited by 3,223
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology
Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisi, J. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00010-8 · Cited by 2,900
Morris, S. B., & DeShon, R. P. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.1.105 · Cited by 2,502
Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002) · Science · doi:10.1126/science.1067176 · Cited by 1,488 · cited 2×
“…(PET) study, analgesia induced by both a placebo and the opioid agonist remifentanil was associated with an increased activity in several pain-modulating brain regions including the rostral anterior cingulate cortex, the orbitotofrontal cortex and the anterior insula (Petrovic et al., 2002).”
BackgroundIkemoto, S., & Panksepp, J. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00023-5 · Cited by 1,450
Dopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131 · cited 2×
“The dopaminergic system, particularly affected in PD, is involved in the regulation of several cognitive, behavioural and sensory-motor functions (Nieoullon, 2002), and notably in reward mechanisms (Ikemoto and Panksepp, 1999; MartinSoelch et al.”
BackgroundMayberg, H. S., Brannan, S. K., Tekell, J. L., Silva, J. A., Mahurin, R. K., McGinnis, S., & Jerabek, P. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01036-2 · Cited by 1,115 · cited 2×
“…however, has also shown that response to both treatment and placebo during pharmacological (Benedetti et al., 2005) and cognitive-behavioural therapy (Mayberg et al., 2000) closely matches the active treatment response that the placebo was designed to stimulate (Lidstone and Stoessl, 2007).”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 2×
“…substantial placebo effects have also been reported in a broad spectrum of disorders of the central nervous system such as insomnia (Perlis et al., 2005) and depression (Walsh et al., 2002; McCall et al., 2003), both conditions that are also associated with RLS (Picchietti and Winkelman, 2005).”
BackgroundTHE MECHANISM OF PLACEBO ANALGESIA
Levine, J., Gordon, N., & Fields, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92762-9 · Cited by 1,094
Amanzio, M., & Benedetti, F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00484.1999 · Cited by 899
How expectancies shape experience.
(1999) · doi:10.1037/10332-000 · Cited by 639
Placebos and painkillers: is mind as real as matter?
Colloca, L., & Benedetti, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1705 · Cited by 465 · cited 2×
“, 2001, 2002) and to subjects with pain disorders or experimentally induced pain (Colloca and Benedetti, 2005). Here, RLS offers the unique possibility Placebo effect in RLS Brain (2008), 131, 902^917 913”
BackgroundInfluentialSomatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia
Benedetti, F., Arduino, C., & Amanzio, M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03639.1999 · Cited by 350
Evaluating the quality of life of patients with restless legs syndrome
Abetz, L., Allen, R., Follet, A., Washburn, T., Early, C., Kirsch, J., & Knight, H. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90136-1 · Cited by 299 · cited 1×
“And indeed, in recent treatment trials, a large placebo effect has been observed (Allen et al., 2004; Trenkwalder et al., 2004; Walters et al., 2004).”
BackgroundIs there a delay in the antidepressant effect? A meta-analysis
Posternak, M. A., & Zimmerman, M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0201 · Cited by 250 · cited 1×
“In both disorders the placebo response increased with study duration (Walach and Maidhof, 1999; Perlis et al., 2005; Posternak and Zimmerman, 2005), a phenomenon we observed also for response rates and RLS severity.”
BackgroundThe strengths and limitations of meta-analyses based on aggregate data
Lyman, G. H., & Kuderer, N. M. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-14 · Cited by 250
Restless Legs Syndrome, Periodic Limb Movements in Sleep, and Depression
(2005) · Sleep · doi:10.1093/sleep/28.7.891 · Cited by 247 · cited 2×
“…substantial placebo effects have also been reported in a broad spectrum of disorders of the central nervous system such as insomnia (Perlis et al., 2005) and depression (Walsh et al., 2002; McCall et al., 2003), both conditions that are also associated with RLS (Picchietti and Winkelman, 2005).”
BackgroundLess is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome
Paulus, W., & Trenkwalder, C. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70576-2 · Cited by 181 · cited 1×
“In contrast to PD, RLS is not a degenerative disorder, and a dopaminergic deficit has not been proven (Paulus and Trenkwalder, 2006).”
Background
Cited by
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
Restless legs syndrome: pathophysiology, clinical presentation and management
Trenkwalder, C., & Paulus, W. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.55 · Cited by 310
Aurora, R. N., Kristo, D. A., Bista, S. R., Rowley, J. A., Zak, R. S., Casey, K. R., Lamm, C. I., Tracy, S. L., & Rosenberg, R. S. (2012) · SLEEP · doi:10.5665/sleep.1988 · Cited by 303
Manconi, M., Garcia-Borreguero, D., Schormair, B., Videnovic, A., Berger, K., Ferri, R., & Dauvilliers, Y. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00311-z · Cited by 271
Innes, K. E., & Selfe, T. K. (2012) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2012/294058 · Cited by 79
Metadata
- Authors
- Fulda, S., & Wetter, T. C.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-02-26
- Volume
- 131
- Issue
- 4
- Pages
- 902-917
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2116484098
- Cited by
- 142
- References
- 19
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.